- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr Morgans on Standardizing the Management of Bone/Cardiac Health With Systemic Therapy in Prostate Cancer
Alicia Morgans, MD, MPH, discusses the importance of managing bone and cardiac health in patients with prostate cancer receiving systemic therapy.
- 2x
- 1.75x
- 1.5x
- 1.25x
- 1x, selected
- 0.75x
- 0.5x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Alicia Morgans, MD, MPH, a physician and medical director of the Survivorship Program at Dana-Farber Cancer Institute; and an associate professor of medicine at Harvard Medical School, underscored the need to standardize the management of bone, cardiac, and other complications in patients undergoing systemic therapy for prostate cancer.
Morgans led a session on the management of the complications of systemic therapy at the 2025 Bridging the Gaps in Prostate Cancer meeting.